3 February 2020 Inventiva selected to present the positive results from its Phase IIa clinical study with odiparcil in MPS VI at the 16th Annual WORLDSymposium

18 December 2019 Inventiva announces positive results from Phase IIa clinical study with odiparcil in mucopolysaccharidosis type VI

2 September 2019 Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults

11 June 2019: Inventiva Announces End of Patient Recruitment for its Phase IIa Trial in the Treatment of MPS VI

5 March 2019: The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI

9 April 2018: Raising new hope for Maroteaux-Lamy Syndrome at The Royal Free

26 February 2018: Inventiva announces positive outcomes of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients

31 January 2018: Inventiva to present in vivo data with odiparcil at the 14th WORLDSymposium™

3 January 2018: Inventiva announces enrolment of first patient into its odiparcil phase IIA tria (iMProveS) for MPS VI

30 November 2017: Save the date: KOL meeting and webcast on Odiparcil, our novel treatment for MPS VI patients (New-York, 8:00-9:30 am EST)

10 October 2017: iMProves Trial featured in the fall issue of the MPS Society (UK) Magazine. To read the article click here.

29 August 2017: Inventiva’s Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the European Medicines Agency 

10 August 2017: Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the FDA 

29 June 2017: Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference

13 July 2016: Poster presentation at the 14th International Symposium on MPS and Related Diseases.